ReviewJournal of the European Academy of Dermatology and Venereology : JEADV2019
Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
Review in Journal of the European Academy of Dermatology and Venereology : JEADV, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials.Journal of immunology research · 2020Pooled it
- Trial
- Treatment Patterns, Drug Survival, and Effectiveness of Tildrakizumab Among Patients with Prior Interleukin-17 Experience in the PPD CorEvitas Psoriasis Registry.Dermatology and therapy · 2026Article
- Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab-IL PSO (Italian Landscape Psoriasis).Dermatology and therapy · 2026Article
- Non-TNF-targeted drugs in rheumatic diseasescombined with latent tuberculosis infection.Clinical and experimental medicine · 2026Review
- Psoriasis: microbiome dysbiosis and pathogenic mechanisms.Frontiers in immunology · 2026Review
- Single-cell RNA sequencing and in vitro validation reveal risankizumab induces anti-inflammatory macrophage polarization in psoriasis.European journal of medical research · 2025Article
- Impact of topical and systemic therapy on carotid-intima media thickness in psoriasis.Archives of dermatological research · 2025Article
- Evolutionary insights into Interleukin-12 family targets across 405 species.Frontiers in immunology · 2025Article
- Mirikizumab: A promising breakthrough in Crohn's disease treatment.Health science reports · 2024Article
- Basic Susceptibility of Patients with Psoriasis under Systemic Therapy for Respiratory Infections: Data from the German Psoriasis Registry PsoBest.Journal of clinical medicine · 2024Article
- Management of Psoriasis Patients with Serious Infectious Diseases.Advances in therapy · 2024Review
- Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities.Dermatology and therapy · 2024Review
- Granzyme K mediates IL-23-dependent inflammation and keratinocyte proliferation in psoriasis.Frontiers in immunology · 2024Article
- Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.Frontiers in immunology · 2024Article
- Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review.Advances in therapy · 2023Review
- A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Article
- Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis.Frontiers in immunology · 2023Article
- Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Psoriasis is a chronic disease that requires long-term treatment. Consequently, understanding the safety and tolerability of any potential treatment over time is critical to effective prescribing. The biologic agents currently available for the treatment of psoriasis target a number of different inflammatory cytokines involved in psoriasis disease pathogenesis. The monoclonal antibodies tildrakizumab, guselkumab and risankizumab target the p19 subunit that is specific to interleukin (IL)-23. This article reviews published data on the safety of these IL-23p19 inhibitors in patients with psoriasis compared with other currently available biologic therapies. Data from randomized, placebo- and active-controlled phase 3 clinical trials show tildrakizumab, guselkumab and risankizumab to have a favourable risk-benefit profile in patients with moderate to severe psoriasis. No significant safety concerns have been observed for any of these IL-23p19 inhibitors in the data published to date. The most commonly reported adverse events (AEs) associated with these agents in phase 3 studies were upper respiratory tract infections. No increase was seen in rates of serious infections, malignancies or major adverse cardiovascular events, with no signals suggestive of an elevated risk of opportunistic infections, active tuberculosis or reactivation of latent tuberculosis infection, mucocutaneous Candida infections, triggering or worsening of inflammatory bowel disease, demyelinating disorders or suicidal ideation. Selectively targeting IL-23p19 may help avoid AEs that have been associated with biologic agents with other mechanisms of action. Data from long-term extension studies and patient registries will further establish the safety profile of IL-23p19 inhibitors for the treatment of moderate to severe psoriasis in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.